探讨结直肠癌中的免疫抑制机制：MDSCs与TGF-β1的相互作用
Exploring Mechanisms of Immunosuppression in Colorectal Cancer: Interaction of MDSCs with TGF-β1
DOI: 10.12677/acm.2025.152546, PDF,   
作者: 陈鹏远：内蒙古医科大学鄂尔多斯临床医学院，内蒙古 鄂尔多斯；鄂尔多斯市中心医院康巴什部普外科，内蒙古 鄂尔多斯；王 亮*：鄂尔多斯市中心医院康巴什部普外科，内蒙古 鄂尔多斯
关键词: 结直肠癌；髓源性抑制细胞；转化生长因子β-1；免疫逃逸；肿瘤微环境；Colorectal Cancer； Myeloid-Derived Suppressor Cells； Transforming Growth Factor β-1； Immune Escape； Tumor Microenvironment
摘要: 结直肠癌(CRC)作为当下严重的健康问题，在一众癌症中具有高发病率和致死率，究其原因，肿瘤微环境中的免疫抑制机制是推动肿瘤进展的重要因素，其中髓源性抑制细胞(MDSCs)和转化生长因子β-1 (TGF-β1)在此过程中发挥着关键作用。MDSCs是一群具有异质性的未成熟髓系细胞，在结直肠癌患者的癌巢及外周血中显著扩增，参与肿瘤的免疫逃逸与转移过程。研究表明，MDSCs在肿瘤微环境中不仅支持癌细胞的生存，还可以通过分泌TGF-β1等免疫抑制因子，重塑免疫微环境，削弱机体的抗肿瘤免疫反应。此外，TGF-β1通过促进MDSCs的生成和功能，形成一种“恶性正反馈”，进一步加剧肿瘤的免疫逃逸。针对MDSCs和TGF-β1的治疗策略已显示出抑制肿瘤进展的潜力，并在临床研究中取得了一定成效。本文旨在总结MDSCs在结直肠癌中作用机制及TGF-β1的关键功能，概述针对MDSCs与TGF-β1的靶向治疗策略，以期为结直肠癌的防治提供新的思路和方向。这些研究为改善患者的免疫状态和提高治疗效果提供了重要参考，为进一步的临床应用铺平了道路。
Abstract: Colorectal cancer (CRC) is a serious health problem that is characterized by high morbidity and lethality. The immunosuppressive mechanism in the tumor microenvironment is an important factor driving tumor progression. In this process, myeloid-derived suppressor cells (MDSCs) and transforming growth factor-β (TGF-β) play key roles. Growth factor β-1 (TGF-β1) plays a pivotal role in this process. MDSCs are a heterogeneous group of immature myeloid cells that are significantly expanded in the cancer nests and peripheral blood of colorectal cancer patients. These cells are involved in the process of immune escape and metastasis of tumors. Research has demonstrated that MDSCs not only support the survival of cancer cells within the tumor microenvironment, but also remodel the immune microenvironment and diminish the body’s anti-tumor immune response by secreting immunosuppressive factors, such as TGF-β1. Moreover, TGF-β1 has been shown to promote the production and function of MDSCs, thereby establishing a “malignant positive feedback loop” that further exacerbates the immune escape of tumors. Therapeutic strategies targeting MDSCs and TGF-β1 have demonstrated potential for the inhibition of tumor progression and have shown efficacy in clinical studies. The aim of this paper is to provide a summary of the mechanism of action of MDSCs in colorectal cancer and the key functions of TGF-β1, and to outline targeted therapeutic strategies against MDSCs and TGF-β1. These strategies are intended to provide new ideas and directions for the prevention and treatment of colorectal cancer. These studies provide a valuable reference for enhancing patients’ immune status and improving therapeutic outcomes, thereby paving the way for further clinical applications.
文章引用：陈鹏远, 王亮. 探讨结直肠癌中的免疫抑制机制：MDSCs与TGF-β1的相互作用[J]. 临床医学进展, 2025, 15(2): 1864-1878. https://doi.org/10.12677/acm.2025.152546

参考文献

[1] Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 74, 229-263. [Google Scholar] [CrossRef] [PubMed]
[2] 姜潇. 新型结直肠癌生物标志物在诊断中的作用[D]: [博士学位论文]. 大连: 大连理工大学, 2019.
[3] 张倩. 激活突变SHP2E76K酪氨酸磷酸酶对结直肠癌发生发展的影响及其分子机制研究[D]: [博士学位论文]. 合肥: 安徽医科大学, 2018.
[4] 漆家康. 结直肠癌患者手术标本中AIM2表达情况及其与临床病理资料关系的研究[D]: [硕士学位论文]. 泸州: 西南医科大学, 2018.
[5] Mojsilovic, S., Mojsilovic, S.S., Bjelica, S. and Santibanez, J.F. (2021) Transforming Growth Factor‐Beta1 and Myeloid‐Derived Suppressor Cells: A Cancerous Partnership. Developmental Dynamics, 251, 85-104. [Google Scholar] [CrossRef] [PubMed]
[6] Waldner, M.J. and Neurath, M.F. (2023) TGFβ and the Tumor Microenvironment in Colorectal Cancer. Cells, 12, Article 1139. [Google Scholar] [CrossRef] [PubMed]
[7] Zhang, H., Li, Z., Wang, L., Tian, G., Tian, J., Yang, Z., et al. (2017) Critical Role of Myeloid-Derived Suppressor Cells in Tumor-Induced Liver Immune Suppression through Inhibition of NKT Cell Function. Frontiers in Immunology, 8, Article 129. [Google Scholar] [CrossRef] [PubMed]
[8] Shang, A., Gu, C., Wang, W., Wang, X., Sun, J., Zeng, B., et al. (2020) Exosomal circPACRGL Promotes Progression of Colorectal Cancer via the miR-142-3p/miR-506-3p-TGF-β1 Axis. Molecular Cancer, 19, Article No. 117. [Google Scholar] [CrossRef] [PubMed]
[9] Lan, X., Wei, D., Fang, L., Wu, X. and Wu, B. (2024) Tumor-associated Macrophage-Derived TGF-β1 Activates GLI2 via the Smad2/3 Signaling Pathway to Affect Cisplatin Resistance in Lung Adenocarcinoma. Technology in Cancer Research & Treatment, 23. [Google Scholar] [CrossRef] [PubMed]
[10] Bodogai, M., Moritoh, K., Lee-Chang, C., Hollander, C.M., Sherman-Baust, C.A., Wersto, R.P., et al. (2015) Immunosuppressive and Prometastatic Functions of Myeloid-Derived Suppressive Cells Rely Upon Education from Tumor-Associated B Cells. Cancer Research, 75, 3456-3465. [Google Scholar] [CrossRef] [PubMed]
[11] Ozawa, Y., Koh, Y., Shibaki, R., Harutani, Y., Akamatsu, H., Hayata, A., et al. (2024) Uncovering the Role of Tumor cGAS Expression in Predicting Response to PD-1/L1 Inhibitors in Non-Small Cell Lung Cancer. Cancer Immunology, Immunotherapy, 74, Article No. 7. [Google Scholar] [CrossRef] [PubMed]
[12] Fu, J., Li, G., Li, X., Song, S., Cheng, L., Rui, B., et al. (2024) Gut Commensal Alistipes as a Potential Pathogenic Factor in Colorectal Cancer. Discover Oncology, 15, Article No. 473. [Google Scholar] [CrossRef] [PubMed]
[13] Mohammed, O.A., Youssef, M.E., Hamad, R.S., Abdel-Reheim, M.A., Saleh, L.A., Alamri, M.M.S., et al. (2024) Unlocking Vinpocetine’s Oncostatic Potential in Early-Stage Hepatocellular Carcinoma: A New Approach to Oncogenic Modulation by a Nootropic Drug. PLOS ONE, 19, e0312572. [Google Scholar] [CrossRef] [PubMed]
[14] Jamialahmadi, H., Nazari, S.E., TanzadehPanah, H., Saburi, E., Asgharzadeh, F., Khojasteh-Leylakoohi, F., et al. (2023) Targeting Transforming Growth Factor Beta (TGF-β) Using Pirfenidone, a Potential Repurposing Therapeutic Strategy in Colorectal Cancer. Scientific Reports, 13, Article No. 14357. [Google Scholar] [CrossRef] [PubMed]
[15] Sanchez-Pino, M.D., Dean, M.J. and Ochoa, A.C. (2021) Myeloid-Derived Suppressor Cells (MDSC): When Good Intentions Go Awry. Cellular Immunology, 362, Article 104302. [Google Scholar] [CrossRef] [PubMed]
[16] Bronte, V., Brandau, S., Chen, S., Colombo, M.P., Frey, A.B., Greten, T.F., et al. (2016) Recommendations for Myeloid-Derived Suppressor Cell Nomenclature and Characterization Standards. Nature Communications, 7, Article No. 12150. [Google Scholar] [CrossRef] [PubMed]
[17] 孙健, 张继明. 髓源性抑制细胞研究进展[J]. 微生物与感染, 2022, 17(6): 386-394.
[18] Wu, Y., Yi, M., Niu, M., Mei, Q. and Wu, K. (2022) Myeloid-Derived Suppressor Cells: An Emerging Target for Anticancer Immunotherapy. Molecular Cancer, 21, Article No. 184. [Google Scholar] [CrossRef] [PubMed]
[19] 胡桃, 冯正权. MDSCs与免疫逃逸及中医药治疗的研究进展[J]. 江西中医药大学学报, 2015, 27(3): 117-120, 124.
[20] Zeng, W., Liu, H., Mao, Y., Jiang, S., Yi, H., Zhang, Z., et al. (2024) Myeloid-Derived Suppressor Cells: Key Immunosuppressive Regulators and Therapeutic Targets in Colorectal Cancer (Review). International Journal of Oncology, 65, Article No. 85. [Google Scholar] [CrossRef] [PubMed]
[21] 邓婉萍, 孙君重. MDSCs的功能研究新发现[J]. 临床肿瘤学杂志, 2015, 20(5): 474-477.
[22] Yang, Z., Zuo, H., Hou, Y., Zhou, S., Zhang, Y., Yang, W., et al. (2024) Dual Oxygen‐Supply Immunosuppression‐Inhibiting Nanomedicine to Avoid the Intratumoral Recruitment of Myeloid‐Derived Suppressor Cells. Small, 20, Article ID: 2406860. [Google Scholar] [CrossRef] [PubMed]
[23] 漆家康. 结直肠癌患者手术标本中AIM2表达情况及其与临床病理资料关系的研究[D]: [硕士学位论文]. 泸州: 西南医科大学, 2018.
[24] Deng, S., Cheng, D., Wang, J., Gu, J., Xue, Y., Jiang, Z., et al. (2023) MYL9 Expressed in Cancer-Associated Fibroblasts Regulate the Immune Microenvironment of Colorectal Cancer and Promotes Tumor Progression in an Autocrine Manner. Journal of Experimental & Clinical Cancer Research, 42, Article No. 294. [Google Scholar] [CrossRef] [PubMed]
[25] Tao, B., Yi, C., Ma, Y., Li, Y., Zhang, B., Geng, Y., et al. (2023) A Novel TGF-β-Related Signature for Predicting Prognosis, Tumor Microenvironment, and Therapeutic Response in Colorectal Cancer. Biochemical Genetics, 62, 2999-3029. [Google Scholar] [CrossRef] [PubMed]
[26] Fu, M., Li, Q., Qian, H., Min, X., Yang, H., Liu, Z., et al. (2024) Exendin-4 Intervention Attenuates Atherosclerosis Severity by Modulating Myeloid-Derived Suppressor Cells and Inflammatory Cytokines in ApoE-/- Mice. International Immunopharmacology, 140, Article 112844. [Google Scholar] [CrossRef] [PubMed]
[27] 陈雪, 王成磊, 杨冰炜, 等. 芍药汤调控MDSCs相关免疫抑制微环境防治慢性肠炎癌变的效应机制[J]. 中国实验方剂学杂志, 2025, 31(1): 10-19.
[28] 褚雪镭. 基于肠道菌群-胆汁酸-免疫轴探讨养肝益中方防治结直肠癌肝转移的作用机制[D]: [博士学位论文]. 北京: 中国中医科学院, 2024.
[29] Liu, A., Yu, C., Qiu, C., Wu, Q., Huang, C., Li, X., et al. (2023) PRMT5 Methylating SMAD4 Activates TGF-β Signaling and Promotes Colorectal Cancer Metastasis. Oncogene, 42, 1572-1584. [Google Scholar] [CrossRef] [PubMed]
[30] 赵安东, 白克运, 尹悦. 十全大补汤联合FOLFOX方案治疗晚期结直肠癌术后的疗效及对患者血清TGF-β1、IL-17水平的影响[J]. 山东中医杂志, 2017, 36(8): 644-646.
[31] Calon, A., Espinet, E., Palomo-Ponce, S., Tauriello, D.V.F., Iglesias, M., Céspedes, M.V., et al. (2012) Dependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis Initiation. Cancer Cell, 22, 571-584. [Google Scholar] [CrossRef] [PubMed]
[32] Lu, J., Kornmann, M. and Traub, B. (2023) Role of Epithelial to Mesenchymal Transition in Colorectal Cancer. International Journal of Molecular Sciences, 24, Article 14815. [Google Scholar] [CrossRef] [PubMed]
[33] Minini, M. and Fouassier, L. (2023) Cancer-Associated Fibroblasts and Extracellular Matrix: Therapeutical Strategies for Modulating the Cholangiocarcinoma Microenvironment. Current Oncology, 30, 4185-4196. [Google Scholar] [CrossRef] [PubMed]
[34] 张小艺. TGF-β1、PDGF-B在TLR4信号通路中作用的研究[D]: [硕士学位论文]. 贵阳: 贵州大学, 2015.
[35] Fasano, M., Pirozzi, M., Miceli, C.C., Cocule, M., Caraglia, M., Boccellino, M., et al. (2024) TGF-β Modulated Pathways in Colorectal Cancer: New Potential Therapeutic Opportunities. International Journal of Molecular Sciences, 25, Article 7400. [Google Scholar] [CrossRef] [PubMed]
[36] Liu, C., Zhang, W., Wang, J., Si, T. and Xing, W. (2021) Tumor‐Associated Macrophage‐Derived Transforming Growth Factor‐β Promotes Colorectal Cancer Progression through HIF1‐TRIB3 Signaling. Cancer Science, 112, 4198-4207. [Google Scholar] [CrossRef] [PubMed]
[37] Rodríguez‐García, A., Samsó, P., Fontova, P., Simon‐Molas, H., Manzano, A., Castaño, E., et al. (2017) TGF‐β1 Targets Smad, p38 MAPK, and PI3K/Akt Signaling Pathways to Induce PFKFB3 Gene Expression and Glycolysis in Glioblastoma Cells. The FEBS Journal, 284, 3437-3454. [Google Scholar] [CrossRef] [PubMed]
[38] Ungefroren, H., Witte, D. and Lehnert, H. (2017) The Role of Small GTPases of the Rho/Rac Family in TGF‐β‐Induced EMT and Cell Motility in Cancer. Developmental Dynamics, 247, 451-461. [Google Scholar] [CrossRef] [PubMed]
[39] MacDonald, W.J., Verschleiser, B., Carlsen, L., Huntington, K.E., Zhou, L. and El-Deiry, W.S. (2023) Broad Spectrum Integrin Inhibitor GLPG-0187 Bypasses Immune Evasion in Colorectal Cancer by TGF-β Signaling Mediated Downregulation of PD-L1. American Journal of Cancer Research, 13, 2938-2947.
[40] Thomas, D.A. and Massagué, J. (2005) TGF-β Directly Targets Cytotoxic T Cell Functions during Tumor Evasion of Immune Surveillance. Cancer Cell, 8, 369-380. [Google Scholar] [CrossRef] [PubMed]
[41] Gorelik, L. and Flavell, R.A. (2002) Transforming Growth Factor-β in T-Cell Biology. Nature Reviews Immunology, 2, 46-53. [Google Scholar] [CrossRef] [PubMed]
[42] Shin, S.H., Lee, Y.E., Yoon, H., Yuk, C.M., An, J.Y., Seo, M., et al. (2025) An Innovative Strategy Harnessing Self-Activating CAR-NK Cells to Mitigate TGF-β1-Driven Immune Suppression. Biomaterials, 314, Article 122888. [Google Scholar] [CrossRef] [PubMed]
[43] Guo, Y., Hu, C., Cai, K., Long, G., Cai, D., Yu, Z., et al. (2024) KRAS Inhibitors May Prevent Colorectal Cancer Metachronous Metastasis by Suppressing TGF-β Mediated Epithelial-Mesenchymal Transition. Molecular Medicine Reports, 31, Article No. 24. [Google Scholar] [CrossRef] [PubMed]
[44] 邵建富, 李兴海, 马文杰, 等. 胃癌患者组织中TGF-α、TGF-β1和miR-302a的表达及其与胃癌的相关性研究[J]. 现代消化及介入诊疗, 2020, 25(5): 629-633.
[45] Batlle, E. and Massagué, J. (2019) Transforming Growth Factor-β Signaling in Immunity and Cancer. Immunity, 50, 924-940. [Google Scholar] [CrossRef] [PubMed]
[46] Lee, C., Lee, W., Cho, S. and Park, S. (2018) Characterization of Multiple Cytokine Combinations and TGF-β on Differentiation and Functions of Myeloid-Derived Suppressor Cells. International Journal of Molecular Sciences, 19, Article 869. [Google Scholar] [CrossRef] [PubMed]
[47] 吴端. 体内外研究18β-甘草次酸对MDSCs免疫抑制功能的影响[D]: [硕士学位论文]. 厦门: 厦门大学, 2014.
[48] Ruixin, S., Yifan, L., Yansha, S., Min, Z., Yiwei, D., Xiaoli, H., et al. (2024) Dual Targeting Chimeric Antigen Receptor Cells Enhance Antitumour Activity by Overcoming T Cell Exhaustion in Pancreatic Cancer. British Journal of Pharmacology, 181, 4628-4646. [Google Scholar] [CrossRef] [PubMed]
[49] Lasser, S.A., Ozbay Kurt, F.G., Arkhypov, I., Utikal, J. and Umansky, V. (2024) Myeloid-Derived Suppressor Cells in Cancer and Cancer Therapy. Nature Reviews Clinical Oncology, 21, 147-164. [Google Scholar] [CrossRef] [PubMed]
[50] 吕川. MSC旁分泌TGF-β通过ERK1/2信号通路诱导黑色素瘤EMT的作用研究[D]: [博士学位论文]. 上海: 中国人民解放军海军军医大学, 2020.
[51] Marvel, D. and Gabrilovich, D.I. (2015) Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Expect the Unexpected. Journal of Clinical Investigation, 125, 3356-3364. [Google Scholar] [CrossRef] [PubMed]
[52] Kim, B.-G., Malek, E., Choi, S.H., Ignatz-Hoover, J.J. and Driscoll, J.J. (2021) Novel Therapies Emerging in Oncology to Target the TGF-β Pathway. Journal of Hematology & Oncology, 14, Article No. 55. [Google Scholar] [CrossRef] [PubMed]
[53] Jayaraman, P., Parikh, F., Newton, J.M., Hanoteau, A., Rivas, C., Krupar, R., et al. (2018) TGF-β1 Programmed Myeloid-Derived Suppressor Cells (MDSC) Acquire Immune-Stimulating and Tumor Killing Activity Capable of Rejecting Established Tumors in Combination with Radiotherapy. OncoImmunology, 7, e1490853. [Google Scholar] [CrossRef] [PubMed]
[54] Zhang, F., Dong, W., Zeng, W., Zhang, L., Zhang, C., Qiu, Y., et al. (2016) Naringenin Prevents TGF-β1 Secretion from Breast Cancer and Suppresses Pulmonary Metastasis by Inhibiting PKC Activation. Breast Cancer Research, 18, Article No. 38. [Google Scholar] [CrossRef] [PubMed]
[55] 杨萍芬, 牛艳芬. TGF-β1/Smad信号通路在组织纤维化中的研究进展[J]. 国际药学研究杂志, 2019, 46(10): 738-744.
[56] Yi, Q., Zhu, G., Zhu, W., Wang, J., Ouyang, X., Yang, K., et al. (2024) Oncogenic Mechanisms of COL10A1 in Cancer and Clinical Challenges (Review). Oncology Reports, 52, Article No. 162. [Google Scholar] [CrossRef] [PubMed]
[57] Yang, Z., Guo, J., Weng, L., Tang, W., Jin, S. and Ma, W. (2020) Myeloid-Derived Suppressor Cells—New and Exciting Players in Lung Cancer. Journal of Hematology & Oncology, 13, Article No. 10. [Google Scholar] [CrossRef] [PubMed]
[58] Sánchez-León, M.L., Jiménez-Cortegana, C., Silva Romeiro, S., Garnacho, C., de la Cruz-Merino, L., García-Domínguez, D.J., et al. (2023) Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells. International Journal of Molecular Sciences, 24, Article 5208. [Google Scholar] [CrossRef] [PubMed]
[59] Shojaei, F., Wu, X., Malik, A.K., Zhong, C., Baldwin, M.E., Schanz, S., et al. (2007) Tumor Refractoriness to Anti-VEGF Treatment Is Mediated by CD11b+Gr1+ Myeloid Cells. Nature Biotechnology, 25, 911-920. [Google Scholar] [CrossRef] [PubMed]
[60] Mehta, A.R. and Armstrong, A.J. (2015) Tasquinimod in the Treatment of Castrate-Resistant Prostate Cancer—Current Status and Future Prospects. Therapeutic Advances in Urology, 8, 9-18. [Google Scholar] [CrossRef] [PubMed]
[61] Yuan, B., Clowers, M.J., Velasco, W.V., Peng, S., Peng, Q., Shi, Y., et al. (2022) Targeting IL-1β as an Immunopreventive and Therapeutic Modality for K-Ras-Mutant Lung Cancer. JCI Insight, 7, e157788. [Google Scholar] [CrossRef] [PubMed]
[62] Flores-Toro, J.A., Luo, D., Gopinath, A., Sarkisian, M.R., Campbell, J.J., Charo, I.F., et al. (2019) CCR2 Inhibition Reduces Tumor Myeloid Cells and Unmasks a Checkpoint Inhibitor Effect to Slow Progression of Resistant Murine Gliomas. Proceedings of the National Academy of Sciences, 117, 1129-1138. [Google Scholar] [CrossRef] [PubMed]
[63] Chiu, D.K., Tse, A.P., Xu, I.M., Di Cui, J., Lai, R.K., Li, L.L., et al. (2017) Hypoxia Inducible Factor HIF-1 Promotes Myeloid-Derived Suppressor Cells Accumulation through ENTPD2/CD39L1 in Hepatocellular Carcinoma. Nature Communications, 8, Article No. 517. [Google Scholar] [CrossRef] [PubMed]
[64] Zahran, A.M., Moeen, S.M., Thabet, A.F., Rayan, A., Abdel-Rahim, M.H., Mohamed, W.M.Y., et al. (2020) Monocytic Myeloid-Derived Suppressor Cells in Chronic Lymphocytic Leukemia Patients: A Single Center Experience. Leukemia & Lymphoma, 61, 1645-1652. [Google Scholar] [CrossRef] [PubMed]
[65] O’Mahony, C., Clooney, A., Clarke, S.F., Aguilera, M., Gavin, A., Simnica, D., et al. (2023) Dietary-Induced Bacterial Metabolites Reduce Inflammation and Inflammation-Associated Cancer via Vitamin D Pathway. International Journal of Molecular Sciences, 24, Article 1864. [Google Scholar] [CrossRef] [PubMed]
[66] Mirza, N., Fishman, M., Fricke, I., Dunn, M., Neuger, A.M., Frost, T.J., et al. (2006) All-trans-Retinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer Patients. Cancer Research, 66, 9299-9307. [Google Scholar] [CrossRef] [PubMed]
[67] Lu, P., Yu, B. and Xu, J. (2012) Cucurbitacin B Regulates Immature Myeloid Cell Differentiation and Enhances Antitumor Immunity in Patients with Lung Cancer. Cancer Biotherapy and Radiopharmaceuticals, 27, 495-503. [Google Scholar] [CrossRef] [PubMed]
[68] Roberts, L.M., Perez, M.J., Balogh, K.N., Mingledorff, G., Cross, J.V. and Munson, J.M. (2022) Myeloid Derived Suppressor Cells Migrate in Response to Flow and Lymphatic Endothelial Cell Interaction in the Breast Tumor Microenvironment. Cancers, 14, Article 3008. [Google Scholar] [CrossRef] [PubMed]
[69] Li, F., Zhao, Y., Wei, L., Li, S. and Liu, J. (2018) Tumor-Infiltrating Treg, MDSC, and IDO Expression Associated with Outcomes of Neoadjuvant Chemotherapy of Breast Cancer. Cancer Biology & Therapy, 19, 695-705. [Google Scholar] [CrossRef] [PubMed]
[70] Christmas, B.J., Rafie, C.I., Hopkins, A.C., Scott, B.A., Ma, H.S., Cruz, K.A., et al. (2018) Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating Mdscs. Cancer Immunology Research, 6, 1561-1577. [Google Scholar] [CrossRef] [PubMed]
[71] Orillion, A., Hashimoto, A., Damayanti, N., Shen, L., Adelaiye-Ogala, R., Arisa, S., et al. (2017) Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. Clinical Cancer Research, 23, 5187-5201. [Google Scholar] [CrossRef] [PubMed]
[72] Tang, Y., Zhou, C., Li, Q., Cheng, X., Huang, T., Li, F., et al. (2022) Targeting Depletion of Myeloid-Derived Suppressor Cells Potentiates PD-L1 Blockade Efficacy in Gastric and Colon Cancers. OncoImmunology, 11, Article 2131084. [Google Scholar] [CrossRef] [PubMed]
[73] Kim, R., Hashimoto, A., Markosyan, N., Tyurin, V.A., Tyurina, Y.Y., Kar, G., et al. (2022) Ferroptosis of Tumour Neutrophils Causes Immune Suppression in Cancer. Nature, 612, 338-346. [Google Scholar] [CrossRef] [PubMed]
[74] Zhao, Y., Lian, J., Lan, Z., Zou, K., Wang, W. and Yu, G. (2021) Ferroptosis Promotes Anti‐Tumor Immune Response by Inducing Immunogenic Exposure in Hnscc. Oral Diseases, 29, 933-941. [Google Scholar] [CrossRef] [PubMed]
[75] Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., et al. (2010) 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity. Cancer Research, 70, 3052-3061. [Google Scholar] [CrossRef] [PubMed]
[76] Ko, J.S., Zea, A.H., Rini, B.I., Ireland, J.L., Elson, P., Cohen, P., et al. (2009) Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients. Clinical Cancer Research, 15, 2148-2157. [Google Scholar] [CrossRef] [PubMed]
[77] Xu, H., Russell, S.N., Steiner, K., O’Neill, E. and Jones, K.I. (2024) Targeting PI3K-Gamma in Myeloid Driven Tumour Immune Suppression: A Systematic Review and Meta-Analysis of the Preclinical Literature. Cancer Immunology, Immunotherapy, 73, Article No. 204. [Google Scholar] [CrossRef] [PubMed]
[78] Qin, H., Lerman, B., Sakamaki, I., Wei, G., Cha, S.C., Rao, S.S., et al. (2014) Generation of a New Therapeutic Peptide That Depletes Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice. Nature Medicine, 20, 676-681. [Google Scholar] [CrossRef] [PubMed]
[79] Wang, H., Liu, R., Yu, Y., Xue, H., Shen, R., Zhang, Y. and Ding, J. (2025) Effects of Cell Shape and Nucleus Shape on Epithelial-Mesenchymal Transition Revealed Using Chimeric Micropatterns. Biomaterials, 317, Article 123013. [Google Scholar] [CrossRef] [PubMed]
[80] Deb, V.K., Chauhan, N. and Jain, U. (2025) Deciphering TGF-β1’s Role in Drug Resistance and Leveraging Plant Bioactives for Cancer Therapy. European Journal of Pharmacology, 988, Article 177218. [Google Scholar] [CrossRef] [PubMed]
[81] Oft, M., Heider, K. and Beug, H. (1998) TGFβ Signaling Is Necessary for Carcinoma Cell Invasiveness and Metastasis. Current Biology, 8, 1243-1252. [Google Scholar] [CrossRef] [PubMed]
[82] Tian, Y., Gao, X., Yang, X., Chen, S. and Ren, Y. (2024) VEGFA Contributes to Tumor Property of Glioblastoma Cells by Promoting Differentiation of Myeloid-Derived Suppressor Cells. BMC Cancer, 24, Article No. 1040. [Google Scholar] [CrossRef] [PubMed]
[83] Bu, M.T., Chandrasekhar, P., Ding, L. and Hugo, W. (2022) The Roles of TGF-β and VEGF Pathways in the Suppression of Antitumor Immunity in Melanoma and Other Solid Tumors. Pharmacology & Therapeutics, 240, Article 108211. [Google Scholar] [CrossRef] [PubMed]
[84] Dahmani, A. and Delisle, J. (2018) TGF-β in T Cell Biology: Implications for Cancer Immunotherapy. Cancers, 10, Article 194. [Google Scholar] [CrossRef] [PubMed]
[85] Tolcher, A.W., Berlin, J.D., Cosaert, J., Kauh, J., Chan, E., Piha-Paul, S.A., et al. (2017) A Phase 1 Study of Anti-TGFβ Receptor Type-II Monoclonal Antibody LY3022859 in Patients with Advanced Solid Tumors. Cancer Chemotherapy and Pharmacology, 79, 673-680. [Google Scholar] [CrossRef] [PubMed]
[86] Hu, Z., Gerseny, H., Zhang, Z., Chen, Y., Berg, A., Zhang, Z., et al. (2011) Oncolytic Adenovirus Expressing Soluble TGFβ Receptor II-Fc-Mediated Inhibition of Established Bone Metastases: A Safe and Effective Systemic Therapeutic Approach for Breast Cancer. Molecular Therapy, 19, 1609-1618. [Google Scholar] [CrossRef] [PubMed]
[87] Lee, J.D., Hempel, N., Lee, N.Y. and Blobe, G.C. (2009) The Type III TGF-β Receptor Suppresses Breast Cancer Progression through GIPC-Mediated Inhibition of TGF-β Signaling. Carcinogenesis, 31, 175-183. [Google Scholar] [CrossRef] [PubMed]
[88] Hau, P., Jachimczak, P., Schlingensiepen, R., Schulmeyer, F., Jauch, T., Steinbrecher, A., et al. (2007) Inhibition of TGF-β2 with AP 12009 in Recurrent Malignant Gliomas: From Preclinical to Phase I/II Studies. Oligonucleotides, 17, 201-212. [Google Scholar] [CrossRef] [PubMed]
[89] Keedy, V.L., Bauer, T.M., Clarke, J.M., Hurwitz, H., Baek, I., Ha, I., et al. (2018) Association of TGF-β Responsive Signature with Anti-Tumor Effect of Vactosertib, a Potent, Oral TGF-β Receptor Type I (TGFBRI) Inhibitor in Patients with Advanced Solid Tumors. Journal of Clinical Oncology, 36, 3031-3031. [Google Scholar] [CrossRef] 
[90] Yap, T.A., Vieito, M., Baldini, C., Sepúlveda-Sánchez, J.M., Kondo, S., Simonelli, M., et al. (2021) First-in-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. Clinical Cancer Research, 27, 6666-6676. [Google Scholar] [CrossRef] [PubMed]
[91] Ciardiello, D., Elez, E., Tabernero, J. and Seoane, J. (2020) Clinical Development of Therapies Targeting TGFβ: Current Knowledge and Future Perspectives. Annals of Oncology, 31, 1336-1349. [Google Scholar] [CrossRef] [PubMed]
[92] Lind, H., Gameiro, S.R., Jochems, C., Donahue, R.N., Strauss, J., Gulley, J.L., et al. (2020) Dual Targeting of TGF-β and PD-L1 via a Bifunctional Anti-PD-L1/TGF-βRII Agent: Status of Preclinical and Clinical Advances. Journal for ImmunoTherapy of Cancer, 8, e000433. [Google Scholar] [CrossRef] [PubMed]
[93] Chang, W., Ragazzi, E., Liu, P. and Wu, S. (2020) Effective Block by Pirfenidone, an Antifibrotic Pyridone Compound (5-Methyl-1-Phenylpyridin-2[H-1]-One), on Hyperpolarization-Activated Cation Current: An Additional but Distinctive Target. European Journal of Pharmacology, 882, Article 173237. [Google Scholar] [CrossRef] [PubMed]
[94] Dione, M.N., Zhang, Q., Shang, S. and Lu, X. (2024) Transcriptomic Analysis of Blood Collagen-Induced Arthritis Mice Exposed to 0.1 THz Reveals Inhibition of Genes and Pathways Involved in Rheumatoid Arthritis. International Journal of Molecular Sciences, 25, Article 12812. [Google Scholar] [CrossRef] [PubMed]
[95] Wu, Q., Miao, X., Zhang, J., Xiang, L., Li, X., Bao, X., et al. (2021) Astrocytic YAP Protects the Optic Nerve and Retina in an Experimental Autoimmune Encephalomyelitis Model through TGF-β Signaling. Theranostics, 11, 8480-8499. [Google Scholar] [CrossRef] [PubMed]
[96] Wu, B., Zhang, S., Guo, Z., Bi, Y., Zhou, M., Li, P., et al. (2021) The TGF-β Superfamily Cytokine Activin-A Is Induced during Autoimmune Neuroinflammation and Drives Pathogenic Th17 Cell Differentiation. Immunity, 54, 308-323.E6. [Google Scholar] [CrossRef] [PubMed]
[97] Gokavi, J., Sadawarte, S., Shelke, A., Kulkarni-Kale, U., Thakar, M. and Saxena, V. (2021) Inhibition of miR-155 Promotes TGF-β Mediated Suppression of HIV Release in the Cervical Epithelial Cells. Viruses, 13, Article 2266. [Google Scholar] [CrossRef] [PubMed]
[98] Ge, Q., Shi, Z., Zou, K., Ying, J., Chen, J., Yuan, W., et al. (2023) Protein Phosphatase PPM1A Inhibition Attenuates Osteoarthritis via Regulating TGF-β/Smad2 Signaling in Chondrocytes. JCI Insight, 8, e166688. [Google Scholar] [CrossRef] [PubMed]
[99] Blaney Davidson, E.N., van der Kraan, P.M. and van den Berg, W.B. (2007) TGF-β and Osteoarthritis. Osteoarthritis and Cartilage, 15, 597-604. [Google Scholar] [CrossRef] [PubMed]
[100] Niu, B., Tian, T., Wang, L., Tian, Y., Tian, T., Guo, Y., et al. (2024) CCL9/CCR1 Axis-Driven Chemotactic Nanovesicles for Attenuating Metastasis of Smad4-Deficient Colorectal Cancer by Trapping TGF-β. Acta Pharmaceutica Sinica B, 14, 3711-3729. [Google Scholar] [CrossRef] [PubMed]
[101] Gneo, L., Rizkalla, N., Hejmadi, R., Mussai, F., de Santo, C. and Middleton, G. (2021) TGF-β Orchestrates the Phenotype and Function of Monocytic Myeloid-Derived Suppressor Cells in Colorectal Cancer. Cancer Immunology, Immunotherapy, 71, 1583-1596. [Google Scholar] [CrossRef] [PubMed]
[102] Lin, X., Xu, W., Shao, M., Fan, Q., Wen, G., Li, C., et al. (2015) Shenling Baizhu San Supresses Colitis Associated Colorectal Cancer through Inhibition of Epithelial-Mesenchymal Transition and Myeloid-Derived Suppressor Infiltration. BMC Complementary and Alternative Medicine, 15, Article No. 126. [Google Scholar] [CrossRef] [PubMed]
[103] 李敏艳. IL-36γ联合TGF-β抗体促进肿瘤免疫应答的效应与机制[D]: [硕士学位论文]. 苏州: 苏州大学, 2022.

为你推荐